Limits...
Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.

Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J - Diabetes Obes Metab (2014)

Bottom Line: In cohort 2, overall, there were contrasting findings between patients in the GLA-S and those in the DET-C subgroup.This study showed contrasting results when patients with T2DM switched between basal insulin analogues, although these preliminary results may be subject to limitations in the analysis.Nevertheless, this study calls into question the therapeutic interchangeability of GLA and DET, and this merits further investigation.

View Article: PubMed Central - PubMed

Affiliation: Model Clinical Research, Baltimore, MD, USA.

Show MeSH

Related in: MedlinePlus

(A) One-year follow-up glycated haemoglobin (HbA1c) values, (B) change in HbA1c from baseline, (C) proportion of patients achieving target HbA1c <7.0%, and (D) proportion of patients achieving target HbA1c <8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383352&req=5

fig03: (A) One-year follow-up glycated haemoglobin (HbA1c) values, (B) change in HbA1c from baseline, (C) proportion of patients achieving target HbA1c <7.0%, and (D) proportion of patients achieving target HbA1c <8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.

Mentions: The baseline mean HbA1c level was similar between the treatment groups in each of the cohorts. In cohort 1, patients in the DET-S subgroup had a significantly higher follow-up HbA1c level (Figure 3A), a significantly lower HbA1c reduction (Figure 3B), and significantly lower proportions of patients achieved HbA1c <7.0% (Figure 3C) and HbA1c <8.0% (Figure 3D) at the end of 1-year follow-up compared with patients in the GLA-C subgroup. In cohort 2, however, compared with patients in the DET-C subgroup, patients in the GLA-S subgroup had a significantly lower follow-up HbA1c (Figure 3A) and a numerically higher (although not statistically significant) HbA1c reduction (Figure 3B), but there were no differences in the proportions of patients achieving an HbA1c level <7.0% (Figure 3C) or <8.0% (Figure 3D).


Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.

Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J - Diabetes Obes Metab (2014)

(A) One-year follow-up glycated haemoglobin (HbA1c) values, (B) change in HbA1c from baseline, (C) proportion of patients achieving target HbA1c <7.0%, and (D) proportion of patients achieving target HbA1c <8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383352&req=5

fig03: (A) One-year follow-up glycated haemoglobin (HbA1c) values, (B) change in HbA1c from baseline, (C) proportion of patients achieving target HbA1c <7.0%, and (D) proportion of patients achieving target HbA1c <8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET.
Mentions: The baseline mean HbA1c level was similar between the treatment groups in each of the cohorts. In cohort 1, patients in the DET-S subgroup had a significantly higher follow-up HbA1c level (Figure 3A), a significantly lower HbA1c reduction (Figure 3B), and significantly lower proportions of patients achieved HbA1c <7.0% (Figure 3C) and HbA1c <8.0% (Figure 3D) at the end of 1-year follow-up compared with patients in the GLA-C subgroup. In cohort 2, however, compared with patients in the DET-C subgroup, patients in the GLA-S subgroup had a significantly lower follow-up HbA1c (Figure 3A) and a numerically higher (although not statistically significant) HbA1c reduction (Figure 3B), but there were no differences in the proportions of patients achieving an HbA1c level <7.0% (Figure 3C) or <8.0% (Figure 3D).

Bottom Line: In cohort 2, overall, there were contrasting findings between patients in the GLA-S and those in the DET-C subgroup.This study showed contrasting results when patients with T2DM switched between basal insulin analogues, although these preliminary results may be subject to limitations in the analysis.Nevertheless, this study calls into question the therapeutic interchangeability of GLA and DET, and this merits further investigation.

View Article: PubMed Central - PubMed

Affiliation: Model Clinical Research, Baltimore, MD, USA.

Show MeSH
Related in: MedlinePlus